Published Technical Disclosure Archive

Enhanced 3-Dimensional Lung-Like Epithelium Formation Systems and Methods

Publication ID: 24-11857697_0001_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced 3-Dimensional Lung-Like Epithelium Formation Systems and Methods,” Published Technical Disclosure No. 24-11857697_0001_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857697_0001_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,697.

Summary of the Inventive Concept

The present inventive concept relates to improved systems and methods for obtaining 3-dimensional lung-like epithelium, enhancing efficiency, scalability, and safety of lung tissue production for research, therapeutic, and transplantation applications.

Background and Problem Solved

The original patent disclosed methods and systems for growing 3-dimensional lung-like epithelium, but had limitations in terms of culturing conditions, growth factor optimization, and scalability. The present inventive concept addresses these limitations by introducing controlled bioreactors, optimized growth factor cocktails, and large-scale production capabilities, thereby improving the efficiency, quality, and safety of lung tissue production.

Detailed Description of the Inventive Concept

The new inventive concept comprises a system for obtaining 3-dimensional lung-like epithelium, featuring a bioreactor configured to culture cells from NKX2.1+ ventral-anterior foregut spheroid tissue derived from pluripotent stem cells, with controlled oxygen levels and temperature. Additionally, the inventive concept includes methods for enhancing efficiency, scaling up production, and real-time monitoring of 3-dimensional lung-like epithelium formation. These methods involve culturing cells in optimized growth factor cocktails, large-scale bioreactors, and microfluidic devices integrated with sensors and imaging systems.

Novelty and Inventive Step

The new inventive concept introduces novel and non-obvious improvements over the original patent, including the use of controlled bioreactors, optimized growth factor cocktails, and large-scale production capabilities, which significantly enhance the efficiency, quality, and safety of lung tissue production.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include the use of different types of bioreactors, growth factor cocktails, or microfluidic devices. Variations may also include the integration of additional sensors or imaging systems to monitor 3-dimensional lung-like epithelium formation.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the fields of regenerative medicine, tissue engineering, and biomedical research, with potential applications in lung disease modeling, drug discovery, and transplantation therapy.

CPC Classifications

SectionClassGroup
A A61 A61L27/3895
A A61 A61K35/42
A A61 A61L27/3804
A A61 A61L27/3813
A A61 A61L27/3834
A A61 A61L27/3839
A A61 A61L27/3869
C C12 C12N5/0018
C C12 C12N5/0062
C C12 C12N5/0606
C C12 C12N5/0607
C C12 C12N5/0688
C C12 C12N5/0689
A A61 A61L2430/22
C C12 C12N2501/113
C C12 C12N2501/115
C C12 C12N2501/117
C C12 C12N2501/119
C C12 C12N2501/155
C C12 C12N2501/385
C C12 C12N2501/415
C C12 C12N2501/999
C C12 C12N2506/02
C C12 C12N2506/03
C C12 C12N2506/27
C C12 C12N2506/45
C C12 C12N2513/00

Field of Art

Regenerative medicine, stem cell biology, tissue engineering, with specific focus on lung epithelial tissue development and in vitro cultivation techniques

Person of Ordinary Skill (PHOSITA) Profile

A biomedical researcher with advanced degree (PhD/MD) in stem cell biology or tissue engineering, experienced in pluripotent stem cell differentiation, cell culture techniques, and bioreactor design, familiar with molecular signaling pathways and tissue regeneration strategies

Obviousness Rationale

A person having ordinary skill would recognize that the PTD's disclosed variations represent predictable engineering improvements to the source patent's fundamental lung epithelium cultivation method. The proposed bioreactor configurations, growth factor optimization, and monitoring techniques are logical extensions of the existing technological framework. These variations demonstrate standard incremental innovation typical in biomedical research, applying known techniques to enhance cell culture efficiency and scalability.

Obvious Combinations & Variations

Source Patent Element
In vitro culturing of NKX2.1+ ventral-anterior foregut spheroid tissue derived from pluripotent stem cells
PTD Variation
Introducing controlled bioreactor systems with regulated oxygen levels and temperature
Obviousness Reasoning
Precise environmental control is a standard optimization technique in cell culture, representing a predictable design choice for improving cellular differentiation outcomes
Source Patent Element
Culturing cells with Wnt and FGF signaling pathway activators
PTD Variation
Developing optimized growth factor cocktails specifically tailored for lung-specific differentiation
Obviousness Reasoning
Refining growth factor combinations is a routine approach in stem cell research, representing an expected method of enhancing cellular differentiation protocols
Source Patent Element
Basic cell culture methods for lung-like epithelium
PTD Variation
Implementing microfluidic devices with integrated sensors for real-time monitoring
Obviousness Reasoning
Incorporating advanced monitoring technologies is a predictable technological progression in biomedical research, representing a logical extension of existing cultivation techniques
Source Patent Element
Pluripotent stem cell-derived tissue culture methods
PTD Variation
Large-scale bioreactor systems with automated control mechanisms
Obviousness Reasoning
Scaling up biological production processes through automated systems is a standard engineering approach in biotechnology, representing an expected method of improving research and therapeutic capabilities
Source Patent Element
Basic cell culture techniques for lung epithelium
PTD Variation
Xenogeneic-free medium supplemented with immunosuppressive factors
Obviousness Reasoning
Developing immunologically safer cultivation methods is a predictable innovation in regenerative medicine, representing a logical refinement of existing tissue culture protocols
35 U.S.C. § 103 Summary: Based on a comprehensive analysis of US Patent 11857697 and the associated Published Technical Disclosure, a person having ordinary skill in the art would find the disclosed variations obvious and non-patentable. The proposed innovations represent standard incremental improvements utilizing known techniques, predictable design choices, and routine optimization strategies within the field of lung epithelial tissue engineering. Consequently, any patent claims substantially similar to the disclosed variations would be rendered obvious by the combination of the source patent and the presented technical disclosure.

Original Patent Information

Patent NumberUS 11,857,697
TitleCompositions and methods for obtaining 3-dimensional lung-like epithelium and related uses thereof
Assignee(s)THE REGENTS OF THE UNIVERSITY OF MICHIGAN